Jazz Pharmaceuticals Plc officer Bruce C. Cozadd filed a Form 144 notice on November 2, 2026, proposing to sell 6,000 shares of Jazz Pharmaceuticals common stock on NASDAQ with an aggregate market value of $1,295,040.

Key Highlights

  • Proposed sale: 6,000 shares of Jazz Pharmaceuticals Plc common stock with an aggregate market value of $1,295,040, filed November 2, 2026.
  • Seller and role: Bruce C. Cozadd, identified in the filing as an officer of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ).
  • Share source: The 6,000 shares were acquired on March 5, 2025 via a stock option exercise from Jazz Pharmaceuticals PLC, with payment made in cash on March 5, 2025.
  • Total shares outstanding: 64,914,577 shares of common stock outstanding, according to the filing.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan adoption date of November 26, 2025.
  • Broker: Merrill Lynch, 3075A Hansen Way 1st Floor, Palo Alto, CA 94304, is named as the broker for the proposed sale.
  • Prior sales disclosed: Three prior sales in the past three months totaling 18,000 shares with gross proceeds of $1,381,980 on October 1, 2026; $1,500,780 on September 1, 2026; and $1,517,880 on August 3, 2026.

Cozadd's Proposed Sale in Context of Jazz Pharmaceuticals' Share Activity

According to the Form 144 filing, Bruce C. Cozadd, an officer of Jazz Pharmaceuticals Plc, a biopharmaceutical company incorporated in Ireland and headquartered in Dublin, proposed to sell 6,000 shares of the company's common stock through Merrill Lynch on or around November 2, 2026. The filing listed an aggregate market value of $1,295,040 for the proposed sale. The shares being sold were originally acquired through a stock option exercise on March 5, 2025, with full cash payment made on the same date, as the filing disclosed.

The filing also references a Rule 10b5-1 plan with an adoption date of November 26, 2025. Under that provision, an officer may establish a prearranged trading plan at a time when they are not in possession of material nonpublic information. The filing includes the standard Form 144 representation that the signing person "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."

As required by Form 144, Cozadd disclosed three prior sales of common stock during the preceding three months: 6,000 shares sold on October 1, 2026 for gross proceeds of $1,381,980; 6,000 shares sold on September 1, 2026 for gross proceeds of $1,500,780; and 6,000 shares sold on August 3, 2026 for gross proceeds of $1,517,880. The company's total common shares outstanding were reported as 64,914,577 at the time of the filing.

What Was Disclosed

Jazz Pharmaceuticals Plc officer Bruce C. Cozadd submitted a Form 144 notice on November 2, 2026, proposing to sell 6,000 shares of common stock on NASDAQ:JAZZ with an aggregate market value of $1,295,040, under a Rule 10b5-1 plan adopted November 26, 2025.